Browse drugs

… index; β=−0.044, 95% CI −0.048 to −0.041), anxiety/depression (EQ-5D-3L q5; β=−0.147, 95% CI −0.160 to −0.134) and fibromyalgia (fibrom…

…emic control (A1C <7%) than those initiating SoC. Additionally, semaglutide initiators had a 1.3% reduction in A1C, compared with a 1.1% re…

…oving patient satisfaction after breast surgery. Traditionally, bupivacaine, a long-acting local anaesthetic, has been widely employed for …

… first multicentre randomised study to evaluate the efficacy of intravenous milrinone in improving the neurological outcomes at 3 months in patients …

…or at least 4 weeks will be randomly assigned to receive either lemborexant (n=50) or placebo (n=50) for 8 weeks. Participants will complet…

…L1 mouse tumor models, we evaluated the therapeutic efficacy of H1A against current FDA-approved PD-L1 blocking antibodies. Using h…

…es in the aspirin-ticagrelor group and 222 cases (7.76%) in the aspirin-clopidogrel group (HR, 0.70; 95% CI, 0.57 to 0.86; p=0.0006). The treatment…

…ed that resolved with the addition of dexamethasone.Conclusions Lacosamide appears to be a promising option for refractory symptoms warran…

…Background In RAISE ( NCT04115293; Phase 3 study), zilucoplan, a macrocyclic peptide complement component 5 inhibitor, demons…

…gnising neuropsychiatric disturbance as a rare manifestation of nitrous oxide neurotoxicity is important, as prompt diagnosis and early vitam…

…uent seizures and motor, behavioral, and cognitive impairments. Fenfluramine was evaluated in three pivotal phase 3 randomized-controlled st…

…th diabetes (n=23), 14 (60.9%) are on insulin, 9 (39.1%) are on metformin, 7 (30.4%) are on SGLT2 inhibitors,5 (14.7%) are on sulfonylure…